Analysts Turn Bullish on Biohaven, Caris, and Veracyte

Canaccord says Biohaven is undervalued and could rise on epilepsy trial results. Jefferies likes Caris Life Sciences and Veracyte, citing strong growth in cancer diagnostics and solid finances.